Transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal complication that can occur after an allogeneic hematopoietic stem cell transplantation (allo-HSCT). Study finds that despite ...

Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology,detailing survival outcomes in adult ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the first report describing the effects of lectin-pathway inhibition by narsoplimab on urinary complement levels in ...

Complement component 3, often called C3, is an essential protein of the immune system. This protein plays a vital role in the body’s innate immune system, providing: the first line of defense against ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the European Medicines Agency (EMA) has appointed rapporteurs for the company’s marketing authorization application ...

Please provide your email address to receive an email when new articles are posted on . SALT LAKE CITY — Sickle cell disease increased risk for transplant-associated thrombotic microangiopathy among ...

Two-part pivotal Phase III study of nomacopan in pediatric patients with HSCT-TMA based on guidance from End-of-Phase II meeting with U.S. Food and Drug Administration (FDA): Part A dose confirmation ...

Omeros Corporation focuses on small-molecule and antibody drugs for common disorders and rare diseases. The company has prioritized the resubmission of its BLA for Narsoplimab for TA-TMA treatment and ...